ArticleArthritis & rheumatology (Hoboken, N.J.)2026
IgG Glycosylation-Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveLupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end-stage kidney disease and increased mortality. IgG from patients with LN displays abnormal glycosylation, contributing to podocyte injury. CLEC7A (C-type lectin domain family 7 member A) is a transmembrane lectin receptor that recognizes fucose on IgG. This study investigates the role of lectin-glycan interactions in LN-related podocyte dysfunction.
methodsIgG isolated from patients with active LN and healthy controls was exposed to differentiated human podocytes. Gene and protein responses were assessed by quantitative polymerase chain reaction, Western blotting, immunofluorescence, phalloidin staining, calcium flux, and wound-healing assays. Human kidney biopsies and MRL/lpr mouse kidneys were examined to validate CLEC7A-spleen tyrosine kinase (SYK) pathway activation and the glycan-dependent effects of LN-IgG.
resultsHuman podocytes exposed to the CLEC7A ligand curdlan or LN-IgG, but not healthy control IgG or IgG from patients with SLE without nephritis, showed increased CLEC7A expression, impaired motility, cytoskeleton disruption, and reduced nephrin expression. Deglycosylation of LN-IgG blocked CLEC7A binding and preserved podocyte function. Mechanistically, curdlan and LN-IgG increased calcium flux and activated SYK. MRL/lpr mice with nephritis exhibited elevated podocyte CLEC7A and SYK expression. Similarly, podocytes in kidney biopsies from patients with active LN exhibit increased expression of SYK and CLEC7A compared with healthy controls. Pharmacological SYK inhibition or CLEC7A silencing prevented podocyte injury.
conclusionWe reveal a novel IgG lectin-glycan-CLEC7A-SYK axis involved in the pathogenesis of LN, which can be targeted therapeutically in patients with LN.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.